image: MRI images of a child with cystic fibrosis: Mucus deposits, widening of the bronchi, and thickening of the bronchial walls are clearly visible in the lungs (left). Six months after receiving triple combination therapy, these changes are nearly completely reversed (right). © Charité | Felix Döllinger
Credit: © Charité | Felix Döllinger
Cystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time. Today, triple combination therapy makes it possible to address the root causes of the defect underlying the disease. This form of treatment was recently approved for children in addition to adults. A recent observational study led by Charité – Universitätsmedizin Berlin shows that the new treatment significantly improves the health status of school-aged children with cystic fibrosis. The results have been published in the European Respiratory Journal.*
People with cystic fibrosis experience a buildup of thick, viscous mucus secretions in the lungs, clogging their airways. This leads to shortness of breath, chronic bacterial infections, inflammation and tissue changes in the lungs, with diminishing lung function. Lifelong symptomatic treatment involving daily inhalation of mucus-thinning medications, antibiotics in certain cases, and physical therapy is recommended for those with the disease.
A new therapeutic concept emerged in 2020 as a way to address not only the symptoms, but the cause of the disease: combination therapy with three drugs called elexacaftor, tezacaftor, and ivacaftor. This “triple combination therapy” is taken as a pill and was approved for children six years and older in 2022 and then, in 2023, starting at the age of two years.
“Having this therapy become available for children is a real blessing for our young patients,” says Prof. Mirjam Stahl, corresponding author of the study and head of the Division of Cystic Fibrosis at the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine at Charité. “In our recent observational study, which we conducted on children ranging in age from six to eleven years, we were able to show that triple combination therapy leads to a significant improvement in the lung disease.”
How the triple combination therapy works
As a disease, cystic fibrosis is based on genetic defects that cause the molecular structures responsible for normal production of mucus that covers the airway surfaces of the lungs, known as CFTR channels, to work inadequately or not at all. CFTR channels regulate the transportation of salt and water across airway surfaces ensure that the mucus formed is liquid enough. About 90 percent of cystic fibrosis patients have a mutation known as F508del, which causes structural damage to the CFTR channel, so it is not functional.
Two of the drugs involved in the triple combination therapy, elexacaftor and tezacaftor, can correct this structural damage. The third one, ivacaftor, acts as a kind of wedge, keeping the CFTR channel open at all times. “Triple combination therapy makes it possible to boost the functioning of the CFTR channel to as much as 50 percent of normal levels,” Stahl says. “We know from a previous observational study of adults that the triple combination therapy is associated with considerable improvement in lung function and quality of life. It’s a true game changer for the majority of patients.”
Lung function comparable to healthy subjects
But how effective is the triple combination therapy in children of elementary school age? The team of researchers led by Stahl and Prof. Marcus Mall, Director of the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and the head of the observational study, aimed to find out. The study was conducted at four German cystic fibrosis centers. In addition to Charité, the Hannover Medical School (MHH), Heidelberg University Hospital, and the University Hospital of Giessen were also involved.
The researchers studied 107 children with cystic fibrosis ranging in age from six to eleven years, both before the treatment started and during the prescribed triple combination therapy. Typical examination methods for gauging lung function, such as spirometry, were paired with new and innovative methods such as multiple breath washout and magnetic resonance imaging (MRI) of the lungs. These methods made it possible to detect and visualize changes in the lungs such as widening of the bronchi, thickening of the bronchial walls, and persistent mucus deposits in great detail.
The team of researchers followed the study participants for about a year. “Triple combination therapy significantly reduced the severity of lung disease in young patients and, at least during the one-year study period, also prevented the disease from progressing,” Mall says, summarizing the results of the study. “The majority of the children even achieved normal lung function with the triple combination therapy. That’s a highly positive result!”
Further research
Stahl and her team are currently conducting a similar observational study of children ranging in age from two to five years to shed further light on the benefits of triple combination therapy in this age group as well. “We hope starting triple combination therapy in early childhood will be able to prevent the emergence of severe symptoms and the formation of structural changes in the lungs,” she says.
The researchers also aim to find out whether the symptom-based therapy for cystic fibrosis can be reduced during triple combination therapy. So far, it has been continued in parallel. Stahl comments: “Needing fewer inhalations would be a huge time saver for patients in day-to-day life and significantly improve their quality of life.”
*Stahl M. et al. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Children with Cystic Fibrosis and One or Two F508del Alleles. Eur Respir J 2024 Jun 20. doi: 10.1183/13993003.00004-2024
About the study
The study’s corresponding author is Prof. Mirjam Stahl (Charité and Berlin Institute of Health at Charité (BIH)). Additional first authors are Dr. Martha Dohna (Hannover Medical School (MHH)), Dr. Simon Gräber (Charité and BIH), and Dr. Olaf Sommerburg (Heidelberg University Hospital). The lead authors of the study are Einstein Professor Marcus Mall (Charité and BIH), Prof. Lutz Nährlich (University Hospital of Giessen), Prof. Jens Vogel-Claussen (MHH), Prof. Burkhard Tümmler (MHH), and Prof. Anna-Maria Dittrich (MHH). The majority of the researchers are active in the German Center for Lung Research (DZL). Funding for the study was provided by Vertex Pharmaceuticals, the German Federal Ministry of Education and Research (BMBF), and the German Research Foundation (DFG).
About cystic fibrosis
Cystic fibrosis is one of the most common fatal hereditary diseases worldwide. As many as 8,000 children, teens, and adults are living with the disease in Germany today. An imbalance in salt and water levels in the body causes people with cystic fibrosis to produce thick, sticky secretions that harm organs such as the lungs and pancreas. This leads to progressive loss of lung function and shortness of breath, which still significantly lowers life expectancy despite advances in treatment. Some 150 to 200 children are born with this rare disease in Germany each year. A test for cystic fibrosis is part of routine screening for newborns.
About the triple combination therapy
A combination of three drugs – elexacaftor, tezacaftor, and ivacaftor – became available in Europe in August 2020. The therapy noticeably improves lung function and quality of life in patients with the most common genetic defect involved in CF, F508del. This means the treatment is an option for nearly 90 percent of those living with cystic fibrosis. The combination therapy was approved for children starting at the age of six years in early 2022 and then for children starting at the age of two years in 2023.
Journal
European Respiratory Journal